Real-World Patterns of Systemic Therapy Attrition Highlight Gaps in TNBC Care
A study published in Breast Cancer Research and Treatment reveals that a significant percentage of patients with triple-negative breast cancer fail to initiate systemic therapy within 90 days of metastatic recurrence. This 'attrition' is associated with poorer survival outcomes and highlights a critical gap in current oncology care strategies.
Why it matters
Identifying these gaps in treatment initiation is essential for improving clinical management and survival rates for aggressive cancer types.
Attrition of early first-line systemic anticancer therapy (SACT) for patients with triple-negative breast cancer (TNBC) “represents a meaningful gap in the care continuum and warrants improved surveillance and multidisciplinary management strategies,” according to a recent study.
A team of researchers from Italy conducted the study and published their findings in Breast Cancer Research and Treatment .
The goal of their study was to “assess the incidence and determinants” of a reduction in early first-line SACT “after metastatic recurrence” in TNBC that has been previously treated with neoadjuvant chemo-immunotherapy.
The “retrospective multicenter analysis” consisted of 209 “consecutive” patients who were diagnosed with early-stage TNBC and who underwent neoadjuvant chemo-immunotherapy. The median follow-up was 24 months, after which 54 patients “developed metastatic recurrence.”
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in